A new kind of clinic
Lately my feed has been full of ads for "deprescribing clinics." The pitch is usually some version of the same promise: we will help you get off your psychiatric medications. Some of these services operate entirely online. Some focus on a single class of medication, most often antidepressants. Many frame stopping medication as the goal of treatment in itself.
I find the idea very strange. Not because stopping medication is wrong, but because a clinic built around one direction of treatment has already decided the answer before meeting the patient.
The broader conversation has also reached the national stage. In May 2026, federal health officials announced a plan to promote appropriate psychiatric prescribing and to support deprescribing when clinically indicated. Professional organizations, including the American Academy of Child and Adolescent Psychiatry (AACAP), responded by reminding the public that these medications, when prescribed thoughtfully and monitored properly, are safe, effective, and for many people lifesaving.
I want to offer a clinician's view on all of this, especially for parents. My view is simple. Treatment cannot be shaped by trends. It must be shaped by the child in front of us, the diagnosis we have carefully made, and the science we have spent decades building.
Deprescribing is not new. It is part of the job.
The word “deprescribing” sounds like a discovery. It is not. It is a new name for something psychiatrists have always been trained to do.
Psychiatric training does not only teach us how to start a medication. It teaches us to ask whether a medication is needed at all, what we expect it to do, how long treatment should last, and when and how to stop. Those questions are not an afterthought. They are part of every treatment plan from the very first visit.
In child and adolescent psychiatry this is even more true. Children grow. Their brains, bodies, schools, and families change from year to year. A medication that made sense at age 9 may not be needed at 13. A dose that worked at 60 pounds may be wrong at 120. Reassessing, adjusting, tapering, and stopping are routine parts of our work, and we are very skilled at them.
So when a business presents deprescribing as a specialty that the rest of psychiatry has neglected, I disagree. Thoughtful discontinuation is not a niche service. It is standard care.
What our practice parameters say
AACAP has published practice parameters and clinical practice guidelines for decades. They exist so that prescribing in children and adolescents rests on evidence and careful clinical reasoning, not on fashion. When you read them, one thing stands out: stopping medication is built into the plan from the start.
The AACAP Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents (2009) lays out 13 principles.
A few of them speak directly to this debate:
Plan every phase. The treatment plan should cover the acute phase, the maintenance phase, and the discontinuation phase, based on the best available evidence.
Give medication a fair trial. Trials should use an adequate dose for an adequate length of time. A trial that is too short or too low tells us very little.
Stopping requires its own plan. The parameter states that a thoughtful and safe plan for discontinuation is as important as a thoughtful plan for starting.
Know when to consider stopping. Discontinuation can be considered after a sustained period of remission, when side effects become unacceptable, or when the medication is no longer effective or needed.
Taper and watch closely. Prescribers are generally encouraged to taper slowly to avoid withdrawal. Children may need to be seen more often during a discontinuation trial than during maintenance.
Condition-specific guidance follows the same logic. For depression, the 2007 AACAP Practice Parameter for Depressive Disorders states that treatment should be continued for 6 to 12 months after response to consolidate gains and prevent relapse, and that some young people will need longer maintenance treatment. The 2023 AACAP Clinical Practice Guideline on Major and Persistent Depressive Disorders continues that emphasis on evidence-based, individualized care. For anxiety, the 2009 parameter suggests monitoring off medication for up to six months after stopping may be reasonable.
In other words, the question was never whether to stop. The question is when, how, and for whom. That answer comes from a careful assessment, not from an advertisement.
When stopping can be dangerous
Not every diagnosis carries the same risk. For some conditions, a planned taper after a period of stability is reasonable and often expected. For others, stopping medication can be a very dangerous move.
Schizophrenia. AACAP’s Practice Parameter for Children and Adolescents With Schizophrenia (2013) describes early-onset schizophrenia as continuous with the adult form of the illness. Antipsychotic medication remains the primary treatment, combined with psychoeducation and psychosocial support. Youth with early-onset illness often have a more difficult course, and many do not respond fully to the medications we have. When a young person has finally found a medication that works, stopping it without a clear reason and close supervision risks a return of psychosis. Each relapse can mean hospitalization, lost school years, and a harder road back.
Bipolar disorder. AACAP’s Practice Parameter for Children and Adolescents With Bipolar Disorder (2007) recommends maintaining the regimen that achieved stabilization for 12 to 24 months. The research behind that recommendation is sobering. In a well-known naturalistic study of adolescents stabilized on lithium, those who stopped soon after discharge relapsed at nearly three times the rate of those who continued. A later double-blind discontinuation trial in children and adolescents supported lithium’s role as maintenance treatment. Mania and severe depression in a teenager are not small setbacks. They can bring risky behavior, school failure, family crisis, and suicide risk.
For these illnesses, a decision to reduce or stop medication belongs in a careful, ongoing conversation between the family, the young person, and a physician who knows the full history. It does not belong in a program whose business model depends on getting people off their medications.
Yes, the field has real problems
I want to be fair. The deprescribing movement did not appear out of nowhere, and some of the concerns behind it are real.
Some children are on more medications than they need. Studies have documented a rise in psychotropic polypharmacy in youth. Some medications are started without a thorough diagnostic evaluation, and some are continued for years without anyone asking whether they are still helping. Many prescribers carry heavy caseloads with little time for follow-up. Withdrawal symptoms, especially from some antidepressants, can be uncomfortable, and for too long they were not discussed openly enough with patients. And families sometimes feel they were not part of the decision in the first place.
These are legitimate problems. They deserve honest attention from our field.
But the answer to imperfect prescribing is better prescribing. It is a careful diagnosis, a clear rationale, informed consent, regular reassessment, and a real plan for how and when treatment will end. The answer is not to treat medication itself as the enemy. We cannot fix the gaps in care by dismissing the science that shows these medications help.
Medications are not magic pills. They do not replace therapy, sleep, nutrition, school support, or family connection. But they are very valuable tools. For a child with severe depression, a teenager with bipolar disorder, or a young person with psychosis, the right medication at the right time can be the difference between surviving a crisis and being able to grow, learn, and live.
What this means for parents
If your child takes a psychiatric medication and you are wondering whether it is still needed, that is a good question to ask. Bring it to your child's psychiatrist.
A good doctor will welcome the conversation.
Here is what a thoughtful discussion about stopping should include:
A review of the diagnosis. Is it still accurate? What has changed since treatment began?
A look at how long your child has been stable.
For many conditions, stopping too soon after improvement raises the risk of relapse.
An honest weighing of benefits and side effects. What is the medication doing now, and at what cost?
Timing. The middle of finals, a family move, or a recent loss is rarely the right moment to make a change.
A gradual taper with a written plan. Abrupt stopping is rarely the right approach.
Closer follow-up, not less. Your child may need more frequent visits during and after a taper.
Clear warning signs. You should know which early symptoms mean it is time to call.
A few things to be cautious about: a service that offers only one outcome, a program that does not ask for your child's full psychiatric history, or advice from online communities that encourages stopping without medical supervision.
At Plena Mind Center, our physicians are board-certified child and adolescent psychiatrists. We start medications when they are indicated, adjust them as children grow, and stop them when the time is right. Each of those decisions is made with the family, guided by the evidence, and focused on one child at a time.
TREATMENT IS NOT A TREND. IT NEVER SHOULD BE.